Why the study?
Does baseline adiponectin or its change predict progression to diabetes in high-risk subjects receiving lifestyle intervention, metformin, or placebo?
Population
Subjects at high risk for diabetes in the Diabetes Prevention Program (DPP)
Comparison
Lifestyle intervention or metformin vs Placebo
Design
Cohort
Authors
Loading...
Baseline adiponectin may refine diabetes risk stratification in high-risk adults; leaves open whether adiponectin modulation prevents progression.
Does baseline adiponectin or its change predict progression to diabetes in high-risk subjects receiving lifestyle intervention, metformin, or placebo?
Baseline adiponectin is a powerful independent predictor of incident diabetes in high-risk subjects, and increases in adiponectin with lifestyle intervention are associated with reduced diabetes risk.
Mather et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: